Research

Energy balance

57.8% of plastic surgeons believe GLP-1 agonists are profitable for business.

Many plastic surgeons see GLP-1 agonists as a profitable addition to their practice.

ModerateSupportsmedium confidence
The majority believed...profitable for business (57.8%).
Sabrina H. Han et al. · Aesthetic Surgery Journal · 2023

Why this rating

The study is based on a cross-sectional survey of plastic surgeons.

Source

Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss

Sabrina H. Han et al. · Aesthetic Surgery Journal · 2023

DOI 10.1093/asj/sjad364

cross-sectional · n=368Cited 34×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →